secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001628280-26-013565
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine FY2025 net loss $201.1M; WD/AATD IND filings on track, CGD BLA planned
--------------------------------------------------------------------------------

- Net loss $201.1M for FY2025, cash $191.4M providing runway into 2027.
- On track to file IND/CTA for Wilson Disease (1H 2026) and AATD (mid-2026); initial clinical data expected 2027.
- Engaging FDA for PM359 in CGD; plans BLA based on Phase 1/2 data published in NEJM, targeting accelerated approval.
- Workforce reduction and deprioritization of CGD program to focus on in vivo liver franchise.
- CF program preclinical proof-of-concept data expected 2026; BMS CAR-T collaboration continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828026013565/0001628280-26-013565-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828026013565/prme-20260303.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-013565

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer